Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma

Clinical Cancer Research

Volumn 17, Issue 23, 2011, Pages 7462-7469

  Fruehauf, John ^a   Lutzky, Jose ^b   McDermott, David ^c   Brown, Charles K ^d   Meric, Jean Baptiste ^e   Rosbrook, Brad ^f   Shalinsky, David R ^f   Liau, Katherine F ^f,h   Niethammer, Andreas G ^f   Kim, Sinil ^f   Rixe, Olivier ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Midwestern Regional Medical Center   (United States)

^e Centre Médical de Bligny   (France)

^f PFIZER INC   (United States)

^g UNIVERSITY OF CINCINNATI   (United States)

^h SYNEOS HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEMOPTYSIS; HOARSENESS; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIMB PAIN; MALE; MELANOMA; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEINURIA; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; TREATMENT RESPONSE; VOMITING; WEAKNESS; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 82555173114     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0534     Document Type: Article

References (46)

1. American Cancer Society. Cancer facts and figures 2011 [monograph on the Internet]. Atlanta: American Cancer Society; 2011 [cited 2011 Jul 11]. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-029771.pdf.
2. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34. (Pubitemid 32786275)
3. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45. (Pubitemid 46630937)
4. Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005;23:9001-7. (Pubitemid 46211484)
5. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30.
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
7. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16. (Pubitemid 29318842)
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: melanoma, v.2. Fort Washington: NCCN [updated 2008; cited 2010 Dec 17]. Available from: http://www.nccn.org/professionals/physician-gls/f- guidelines.asp.
9. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308. (Pubitemid 351430867)
10. Sosman JA, Puzanov I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res 2006;12:2376s-83s.
11. Egberts F, Kahler KC, Livingstone E, Hauschild A. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. Onkologie 2008;31:398-403. (Pubitemid 351967579)
12. Gonzalez-Cao M, Viteri S, Diaz-Lagares A, Gonzalez A, Redondo P, Nieto Y, et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology 2008;74:12-6. (Pubitemid 351915004)
13. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008;26:2178-85.
14. Laber DA, Okeke RI, Arce-Lara C, Taft BS, Schonard CL, McMasters KM, et al. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. J Cancer Res Clin Oncol 2006;132:611-6. (Pubitemid 44078530)
15. Chapman PB, Hauschild A, Robert C, Larkin JMG, Haanen JBAG, Ribas A, et al. Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. J Clin Oncol 2011;29 (suppl; abstr LBA4).
16. Abe R, Fujita Y, Yamagishi S. Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. Mini Rev Med Chem 2007; 7:649-61. (Pubitemid 47099184)
17. Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol 2007;34:555-65. (Pubitemid 350236307)
18. Grant SW, Kyshtoobayeva AS, Kurosaki T, Jakowatz J, Fruehauf JP. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect Prev 1998;22:185-94. (Pubitemid 28226749)
19. Einspahr JG, Thomas TL, Saboda K, Nickolof BJ, Warneke J, Curiel-Lewandrowski C, et al. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer 2007;110:2519-27. (Pubitemid 350174939)
20. Zhang S, Zhang D, Sun B. Vasculogenic mimicry: current status and future prospects. Cancer Lett 2007;254:157-64. (Pubitemid 47126687)
21. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001;19:577-83. (Pubitemid 32112873)
22. Lev DC, Onn A, Melinkova VO, Miller C, Stone V, Ruiz M, et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 2004;22:2092-100. (Pubitemid 41095142)
23. Gille J, Heidenreich R, Pinter A, Schmitz J, Boehme B, Hicklin DJ, et al. Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. Int J Cancer 2007;120:1899-908. (Pubitemid 46418365)
24. Mouawad R, Spano JP, Comperat E, Capron F, Khayat D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer 2009;45:1407-14.
25. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21. (Pubitemid 44511625)
26. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52. (Pubitemid 38821812)
27. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14:7272-83.
28. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8:975-84. (Pubitemid 47629888)
29. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13.
30. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-8.
31. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009;27:3836-41.
32. Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008;371:2101-8.
33. Rini BI, Escudier B, Tomczak P, Kaprin A, Hutson TE, Szczylik C, et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol 2011;29 (suppl; abstr 4503).
34. Deprimo SE, Bello CL, Smeraglia J, BaumCM, Spinella D, Rini BI, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.
35. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2004;2:315-26. (Pubitemid 39025294)
36. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
37. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34. (Pubitemid 351264344)
38. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009;54:652-8.
39. Tejpar S, Peeters M, Humblet Y, Gelderblom H, Vermorken J, Viret F, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. J Clin Oncol 2007;25:172s (suppl; abstr 4037).
40. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011;17:3841-9.
41. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008;9:117-23.
42. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-93. (Pubitemid 46178407)
43. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 2007;9:320-8. (Pubitemid 47377031)
44. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007;14:1860-9. (Pubitemid 46870935)
45. Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, et al. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol 2007;4:316-21.
46. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 2007;104:17069-74. (Pubitemid 350210993)